Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy

Acta Diabetologica

Volumn 49, Issue 4, 2012, Pages 315-325

  Zhao, Ying Zheng ^a   Li, Xing ^a   Lu, Cui Tao ^a   Xu, Yan Yan ^b   Lv, Hai Feng ^a   Dai, Dan Dan ^a   Zhang, Lu ^a   Sun, Chang Zheng ^a   Yang, Wei ^a   Li, Xiao Kun ^a   Zhao, Ya Ping ^c   Fu, Hong Xing ^a   Cai, Lu ^a   Lin, Min ^a   Chen, Li Juan ^a   Zhang, Ming ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI CENTRAL HOSPITAL   (China)

^c THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes therapy; Insulin; Nanoparticles; Pulmonary administration

Indexed keywords

GELATIN; GLYCERALDEHYDE; INSULIN; NANOPARTICLE; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DEVICES; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; FLUORESCENCE; LIGHT SCATTERING; MORPHOLOGY; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL;

ABSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; DRUG DELIVERY SYSTEMS; EMULSIONS; FEASIBILITY STUDIES; FLUORESCEIN-5-ISOTHIOCYANATE; GELATIN; GLYCERALDEHYDE; HYPOGLYCEMIC AGENTS; INSULIN; LUNG; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; POLOXAMER; PULMONARY ALVEOLI; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84864924841     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-011-0356-z     Document Type: Article

References (34)

1. Yang W, Peters JI, Williams RO 3rd (2008) Inhaled nanoparticles- a current review. Int J Pharm 356(1-2):239-247
2. Patton JS, Byron PR (2007) Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:67-74
3. Malgorzata S, Thierry V, Adam S (2008) Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory disease. Int J Nanomedicine 3(1):1-19
4. Lim SH, Park HW, Shin CH, Know JH, Kim CW (2009) Human insulin microcrystals with lactose carriers for pulmonary delivery. Biosci Biotechnol Biochem 73(12):2576-2582
5. ZhaoYZ, Xu YY, Li X, Lu CT, Zhang L, Dai DD, Sun CZ, Lv HF, Li XK, Yang W (2011) An in vivo experiment to improve pulmonary absorption of insulin using microbubbles. Diabetes Technol Ther. [Epub ahead of print]
6. Xu YY, Lu CT, Fu HX, Zhao YZ, Yang W, Li X, Zhang L, Li XK, Zhang M (2011) Comparing the enhancement efficiency between liposomes and microbubbles for insulin pulmonary absorption. Diabetes Technol Ther 13(7):759-765
7. Jani R, Triplitt C, Reasner C, Defronzo RA (2007) First approved inhaled insulin therapy for diabetes mellitus. Expert Opin Drug Deliv 4:63-76
8. Yousefzade G, Nakhaee A (2011) Insulin-induced hypoglycemia and stress oxidative state in healthy people. Acta Diabetol. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed?term=Insulin- induced%20hypoglycemia%20and%20stress%20oxidative%20state%20in%20healthy%20peo ple
9. Mastrandrea LD (2010) Inhaled insulin: overview of a novel route of insulin administration. Vasc Health Risk Manag 6:47-58
10. Niven RW (1995) Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 12:151-231
11. Siekmeier R, Scheuch G (2008) Systemic treatment by inhalation of macromolecules-Principles, problems and examples. J Physiol Pharmacol 59(Suppl 6):53-79
12. Plumley C, Gorman EM, El-Gendy N, Bybee CR, Munson EJ, Berkland C (2009) Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int J Pharm 369: 136-143
13. Bailey MM, Berkland CJ (2009) Nanoparticle formulations in pulmonary drug delivery. Med Res Rev 29:196-212
14. Tiwari SB, Amiji MM (2006) A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 3:219-232
15. Mansour HM, Rhee YS, Wu X (2009) Nanomedicine in pulmonary delivery. Int J Nanomedicine 4:299-319
16. Vandelli MA, Rivasi F, Guerra P, Forni F, Arletti R (2001) Gelatin microspheres crosslinked with D,L-glyceraldehyde as a potential drug delivery system: preparation, characterisation, in vitro and in vivo studies. Int J Pharm 215:175-184
17. Forni F, Vandelli MA, Cameroni R (1992) Influence of drug loading level on drug release and dynamic swelling of crosslinked gelatin microspheres. J Microencapsul 9:29-39
18. Spurney CF, Guerron AD, Yu Q, Sali A, van der Meulen JH, Hoffman EP, Nagaraju K (2011) Membrane sealant poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord 11:20
19. Lombry C, Bosquillon C, Preat V, Vanbever R (2002) Confocal imaging of rat lungs following intratracheal delivery of dry powders or solutions of fluorescent probes. J Control Release 83:331-341
20. Jurima-Romet M, Shek PN (1991) Lung uptake of liposome entrapped glutathione after intratracheal administration. J Pharm Pharmacol 43:6-10
21. Elliott RB, Edgar BW, Pilcher CC, Quested C, McMaster J (1987) Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J 23(5):293-297
22. Celek A, Celebi N, Tirnaksiz F, Tay A (2005) A lecithin-based microemulsion of Rhinsulin with aprotinin for oral administration: investigation of hypoglycemic effects in nondiabetic and STZ-induced diabetic rats. Int J Pharm 298:176-185
23. Builders PF, Kunle OO, Okpaku LC, Builders MI, Attama AA, Adikwu MU (2008) Preparation and evaluation of mucinated sodium alginate microparticles for oral delivery of insulin. Eur J Pharm Biopharm 70(3):777-783
24. Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP (2010) Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm 385(1-2):143-149
25. Park SH, Kwon JH, Lim SH, Park HW, Kim CW (2007) Characterization of human insulin microcrystals and their absorption enhancement by protease inhibitors in rat lungs. Int J Pharm 339:205-212
26. Byron PR, Patton JS (1994) Drug delivery via the respiratory tract. J Aerosol Med 7:49-75
27. Edwards DA, Dunbar C (2002) Bioengineering of therapeutic aerosols. Annu Rev Biomed Eng 4:93-107
28. Chono S, Tanino T, Seki T, Morimoto K (2006) Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Target 14:557-566
29. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Lunts A, Kreyling W, Cox C (2002) Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J Toxicol Environ Health A 65:1531-1543
30. Packhaeuser CB, Lahnstein K, Sitterberg J, Schmehl T, Gessler T, Bakowsky U, Seeger W, Kissel T (2009) Stabilization of aerosolizable nano-carriers by freezedrying. Pharm Res 26(1): 129-138
31. Harush-Frenkel O, Bivas-Benita M, Nassar T, Springer C, Sherman Y, Avital A, Altschuler Y, Borlak J, Benita S (2010) A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. Toxicol Appl Pharmacol 246(1-2):83-90
32. Perez-Maraver M, Caballero-Corchuelo J, Boltana A, Insa R, Soler J, Montanya E (2011) Comparison of human insulin and insulin analogues on hypoglycaemia and metabolic variability in type 1 diabetes using standardized measurements (HYPO score and Lability Index). Acta Diabetol. [Epub ahead of print] http://www.springerlink.com/content/g1g5856546j20857
33. Sahin SB, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz C (2010) The importance of anti-insulin antibody in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion or multiple daily insulin injections therapy. Acta Diabetol 47(4):325-330
34. Gentile S, Agrusta M, Guarino G, Carbone L, Cavallaro V, Carucci I, Strollo F (2011) Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetol 48(2):121-125